Antibody-targeted chemotherapy-induced remission and stem-cell transplantation prolong disease-free survival for leukemia patients

December 02, 2000

Fred Hutchinson Cancer Research Center researcher presents study results at the American Society of Hematology Meeting in San Francisco

SEATTLE - December 4, 2000 - Patients with acute myeloid leukemia (AML) who achieve remission with the antibody-targeted chemotherapy agent Mylotarg™ (gemtuzumab ozogamicin for injection) have prolonged disease-free survival following stem cell transplantation according to research presented today at the annual meeting of the American Society of Hematology (ASH). These early data, from clinical studies conducted at the Fred Hutchinson Cancer Research Center and other centers, suggest that pre-transplant therapy with Mylotarg can enable patients to receive curative therapy in the form of hematopoietic stem cell transplantation.

AML is among the most serious forms of adult leukemia, with a relatively high fatality rate. It is an aggressive form of cancer in which certain white blood cells become cancerous and rapidly accumulate in the bone marrow, preventing normal marrow from growing and functioning properly. Most AML patients undergo intensive chemotherapy to achieve complete remission, and some also must undergo bone marrow transplants. Because standard chemotherapy drugs to treat AML are non-specific - destroying normal as well as malignant cells - patients who receive the therapy tend to become very sick.

"Intensive chemotherapy is a real challenge for most patients. Mylotarg is different because it has enabled us to achieve remissions with less severe side effects," said Eric Sievers, M.D., of Fred Hutchinson Cancer Research Center. "Our study shows that if a patient achieves remission with Mylotarg and subsequently receives a hematopoietic stem cell transplant, they have an excellent chance of prolonged disease-free survival."

Twenty-two patients with AML in first relapse who achieved remissions with Mylotarg received hematopoietic stem cell transplantation (HSCT). Eleven patients received allogeneic and 11 received autologous hematopoietic stem cell transplants. A majority of patients were alive without leukemia one year after the transplant. At the time of data cutoff, the median relapse-free survival for the 22 patients was 17.4 months after transplant.

"We believe that hematopoietic stem cell transplants appear to cause fewer complications than bone marrow transplants and that Mylotarg appears to cause fewer severe side effects than standard chemotherapy," Sievers continued. "This study shows us that we can offer our high-risk patients tolerable treatment that may prolong their chances of survival."
Researchers at the Fred Hutchinson Cancer Research Center, and eleven other leading leukemia centers, including University of Chicago Medical Center, MD Anderson Cancer Center, The University of Pennsylvania Cancer Center, Wayne State University, and the City of Hope Medical Center, are working with Wyeth-Ayerst Laboratories and Celltech Chiroscience to study Mylotarg, an antibody-drug conjugate that targets chemotherapy treatment to leukemia cells. Mylotarg was approved by the U.S. Food and Drug Administration on May 18, 2000, and is manufactured by Wyeth-Ayerst Laboratories.

The Fred Hutchinson Cancer Research Center is an independent, non-profit research institution dedicated to the development and advancement of biomedical technology to eliminate cancer and other potentially fatal diseases. Recognized internationally for its pioneering work in bone marrow transplantation, the Center has four scientific divisions collaborating to form a unique environment for conducting basic and applied science. One of 35 National Cancer Institute-designated comprehensive cancer centers in the country, it is the only one in the Northwest. Visit the Hutchinson Center web site for more information at

Advancing knowledge, saving lives

For information about Wyeth-Ayerst Laboratories, contact: Douglas Petkus, 610/902-7336. Mylotarg™: Mylotarg is a trademark of American Home Products Corp.

Fred Hutchinson Cancer Research Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to